Research progress on the effects of different dosing regimens of anti-vascular endothelial growth factor drugs on diabetic retinopathy_Chinese Journal of Ocular Fundus Diseases

Authors：

Yisihare Julaiti ¹ ,  Tian Yanming ²

1. Graduate School, Xinjiang Medical University, Urumqi 830011, China;
2. Department of Ophthalmology, General Hospital of Xinjiang, Urumqi 830011, China;

Corresponding author：

Tian Yanming, Email: tianyanming@163.com

Keywords：

Diabetic retinopathy; Anti-vascular endothelial growth factor drug; Dosage regimen; Pars plana vitrectomy; Review

DOI：

10.3760/cma.j.cn511434-20240708-00255

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Diabetic retinopathy (DR) has become an important cause of irreversible vision loss worldwide. Intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs is an important method to the treatment of DR. However, the current anti-VEGF treatment regimen is not uniform. Anti-VEGF injection was preferred and then delayed combined with laser had better prognostic effect. The best time for operation was 5-7 days after injection of anti-VEGF drugs. Pars plana vitrectomy, intraoperative and postoperative on-demand anti-VEGF drugs injection can significantly improve patient prognosis and reduce complications, but further research is needed to strike a balance between the economic burden and the number of injections. Various anti-VEGF drugs have their own advantages for different diseases and should be selected according to the characteristics of the diseases and drugs. Anti-VEGF drugs combined with antioxidants may further improve DR outcomes. Future studies should pay more attention to the optimization and personalization of anti-VEGF drugs application programs to meet the therapeutic needs of different patients.

Citation： Yisihare Julaiti, Tian Yanming. Research progress on the effects of different dosing regimens of anti-vascular endothelial growth factor drugs on diabetic retinopathy. Chinese Journal of Ocular Fundus Diseases, 2025, 41(1): 63-68. doi: 10.3760/cma.j.cn511434-20240708-00255 Copy

1.
2.
3.	Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications[J/OL]. Redox Biol, 2020, 37: 101799[2020-11-13]. https://pubmed.ncbi.nlm.nih.gov/33248932/. DOI: 10.1016/j.redox.2020.101799.
4.	Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030[J/OL]. Front Endocrinol (Lausanne), 2024, 13: 1077669[2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/36699020/. DOI: 10.3389/fendo.2022.1077669.
5.
6.	Julius A, Renuka RR, Hopper W, et al. Inhibition of aldose reductase by novel phytocompounds: a heuristic approach to treating diabetic retinopathy[J/OL]. Evid Based Complement Alternat Med, 2022, 2022: 9624118[2022-03-21]. https://pubmed.ncbi.nlm.nih.gov/35356240/. DOI: 10.1155/2022/9624118.
7.	刘家琦,李凤鸣. 视网膜病[M]//刘家琦, 李凤鸣. 实用眼科学. 北京: 人民卫生出版社, 2010: 207-215.Liu JQ, Li FM. Retinopathy[M]//Liu JQ, Li FM. Practical ophthalmology. Beijing: People's Medical Publishing House, 2010: 207-215.
8.
9.	Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments[J/OL]. Int J Mol Sci, 2018, 19(6): 1816[2018-06-20]. https://pubmed.ncbi.nlm.nih.gov/29925789/. DOI: 10.3390/ijms19061816.
10.
11.
12.
13.
14.	Wang Z, Feng C, Yang R, et al. Large-area photoreceptor degeneration model in rabbits by photocoagulation and oxidative stress in the retina[J/OL]. Front Neurosci, 2021, 15: 617175[2021-06-10]. https://pubmed.ncbi.nlm.nih.gov/34177442/. DOI: 10.3389/fnins.2021.617175.
15.
16.
17.
18.
19.	Yusuf IH, Henein C, Sivaprasad S. Infographic: panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy (PDR): DRCR. net Protocol S[J/OL]. Eye (Lond), 2023, 2023: E1(2023-04-21)[2024-07-08]. https://pubmed.ncbi.nlm.nih.gov/37085719/. DOI: 10.1038/s41433-023-02396-0. [published online ahead of print].
20.
21.
22.	Chen J, Wang H, Qiu W. Intravitreal anti-vascular endothelial growth factor, laser photocoagulation, or combined therapy for diabetic macular edema: a systematic review and network meta-analysis[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1096105[2023-02-02]. https://pubmed.ncbi.nlm.nih.gov/36817588/. DOI: 10.3389/fendo.2023.1096105.
23.
24.
25.
26.
27.
28.
29.	徐玥. PDR围手术期玻璃体内抗VEGF药物注射的最佳时机初探[D]. 淮南: 安徽理工大学, 2021.Xu Y. A preliminary study on the optimal timing of intravitreal anti-VEGF drug injection during the perioperative period of PDR[D]. Huainan: Anhui University of Science and Technology, 2021.
30.
31.
32.
33.	赵宇. 玻璃体切割术联合康柏西普治疗增殖性糖尿病视网膜病变的疗效研究[D]. 沈阳: 中国医科大学, 2022.Zhao Y. Efficacy of vitrectomy combined with conbercept in the treatment of proliferative diabetic retinopathy[D]. Shenyang: China Medical University, 2022.
34.
35.	白旭旭. 增殖性糖尿病视网膜病变患者玻璃体切除术后不同抗VEGF治疗方案的疗效比较[D]. 延安: 延安大学, 2023.Bai XX. Comparison of the efficacy of different anti-VEGF treatment regimens in patients with proliferative diabetic retinopathy after vitrectomy[D]. Yan'an: Yan'an University, 2023.
36.	Tang Y, Shi Y, Fan Z. The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1102361[2023-01-23]. https://pubmed.ncbi.nlm.nih.gov/36755912/. DOI: 10.3389/fendo.2023.1102361.
37.
38.
39.
40.
41.
42.
43.	Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review[J/OL]. Int J Mol Sci, 2022, 23(16): 9424[2022-08-20]. https://pubmed.ncbi.nlm.nih.gov/36012690/. DOI: 10.3390/ijms23169424.
44.
45.	Wijesingha N, Gibson K, Willis JR, et al. Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from yosemite and rhine)[J/OL]. Eye (Lond), 2024, 2024: E1(2024-07-29)[2021-07-08]. https://pubmed.ncbi.nlm.nih.gov/39075261/. DOI: 10.1038/s41433-024-03249-0. [published online ahead of print].
46.	Wang M, Wang L, Gong Y, et al. Study on the effects of different anti-vegf drugs on fibrovascular membranes of proliferative diabetic retinopathy[J/OL]. Photodiagnosis Photodyn Ther, 2023, 42: 103530[2023-04-14]. https://pubmed.ncbi.nlm.nih.gov/37060987/. DOI: 10.1016/j.pdpdt.2023.103530.
47.
48.
49.
50.
51.
52.	Li S, Tao Y, Yang M, et al. Aflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema: a 12-month clinical trial[J/OL]. Front Endocrinol (Lausanne), 2024, 15: 1286736[2024-02-22]. https://pubmed.ncbi.nlm.nih.gov/38455651/. DOI: 10.3389/fendo.2024.1286736.
53.
54.	Gao J, Tao L, Jiang Z. Alleviate oxidative stress in diabetic retinopathy: antioxidant therapeutic strategies[J/OL]. Redox Rep, 2023, 28(1): 2272386[2023-12-02]. https://pubmed.ncbi.nlm.nih.gov/38041593/. DOI: 10.1080/13510002.2023.2272386.
55.
56.
57.
58.	Lee CH, Lui DT, Cheung CY, et al. Circulating AFABP, FGF21, and PEDF levels as prognostic biomarkers of sight-threatening diabetic retinopathy[J/OL]. J Clin Endocrinol Metab, 2023, 108(9): e799-e806[2023-08-18]. https://pubmed.ncbi.nlm.nih.gov/36856742/. DOI: 10.1210/clinem/dgad112.
59.

1.
2.
3. Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications[J/OL]. Redox Biol, 2020, 37: 101799[2020-11-13]. https://pubmed.ncbi.nlm.nih.gov/33248932/. DOI: 10.1016/j.redox.2020.101799.
4. Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030[J/OL]. Front Endocrinol (Lausanne), 2024, 13: 1077669[2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/36699020/. DOI: 10.3389/fendo.2022.1077669.
5.
6. Julius A, Renuka RR, Hopper W, et al. Inhibition of aldose reductase by novel phytocompounds: a heuristic approach to treating diabetic retinopathy[J/OL]. Evid Based Complement Alternat Med, 2022, 2022: 9624118[2022-03-21]. https://pubmed.ncbi.nlm.nih.gov/35356240/. DOI: 10.1155/2022/9624118.
7. 刘家琦,李凤鸣. 视网膜病[M]//刘家琦, 李凤鸣. 实用眼科学. 北京: 人民卫生出版社, 2010: 207-215.Liu JQ, Li FM. Retinopathy[M]//Liu JQ, Li FM. Practical ophthalmology. Beijing: People's Medical Publishing House, 2010: 207-215.
8.
9. Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments[J/OL]. Int J Mol Sci, 2018, 19(6): 1816[2018-06-20]. https://pubmed.ncbi.nlm.nih.gov/29925789/. DOI: 10.3390/ijms19061816.
10.
11.
12.
13.
14. Wang Z, Feng C, Yang R, et al. Large-area photoreceptor degeneration model in rabbits by photocoagulation and oxidative stress in the retina[J/OL]. Front Neurosci, 2021, 15: 617175[2021-06-10]. https://pubmed.ncbi.nlm.nih.gov/34177442/. DOI: 10.3389/fnins.2021.617175.
15.
16.
17.
18.
19. Yusuf IH, Henein C, Sivaprasad S. Infographic: panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy (PDR): DRCR. net Protocol S[J/OL]. Eye (Lond), 2023, 2023: E1(2023-04-21)[2024-07-08]. https://pubmed.ncbi.nlm.nih.gov/37085719/. DOI: 10.1038/s41433-023-02396-0. [published online ahead of print].
20.
21.
22. Chen J, Wang H, Qiu W. Intravitreal anti-vascular endothelial growth factor, laser photocoagulation, or combined therapy for diabetic macular edema: a systematic review and network meta-analysis[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1096105[2023-02-02]. https://pubmed.ncbi.nlm.nih.gov/36817588/. DOI: 10.3389/fendo.2023.1096105.
23.
24.
25.
26.
27.
28.
29. 徐玥. PDR围手术期玻璃体内抗VEGF药物注射的最佳时机初探[D]. 淮南: 安徽理工大学, 2021.Xu Y. A preliminary study on the optimal timing of intravitreal anti-VEGF drug injection during the perioperative period of PDR[D]. Huainan: Anhui University of Science and Technology, 2021.
30.
31.
32.
33. 赵宇. 玻璃体切割术联合康柏西普治疗增殖性糖尿病视网膜病变的疗效研究[D]. 沈阳: 中国医科大学, 2022.Zhao Y. Efficacy of vitrectomy combined with conbercept in the treatment of proliferative diabetic retinopathy[D]. Shenyang: China Medical University, 2022.
34.
35. 白旭旭. 增殖性糖尿病视网膜病变患者玻璃体切除术后不同抗VEGF治疗方案的疗效比较[D]. 延安: 延安大学, 2023.Bai XX. Comparison of the efficacy of different anti-VEGF treatment regimens in patients with proliferative diabetic retinopathy after vitrectomy[D]. Yan'an: Yan'an University, 2023.
36. Tang Y, Shi Y, Fan Z. The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1102361[2023-01-23]. https://pubmed.ncbi.nlm.nih.gov/36755912/. DOI: 10.3389/fendo.2023.1102361.
37.
38.
39.
40.
41.
42.
43. Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review[J/OL]. Int J Mol Sci, 2022, 23(16): 9424[2022-08-20]. https://pubmed.ncbi.nlm.nih.gov/36012690/. DOI: 10.3390/ijms23169424.
44.
45. Wijesingha N, Gibson K, Willis JR, et al. Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from yosemite and rhine)[J/OL]. Eye (Lond), 2024, 2024: E1(2024-07-29)[2021-07-08]. https://pubmed.ncbi.nlm.nih.gov/39075261/. DOI: 10.1038/s41433-024-03249-0. [published online ahead of print].
46. Wang M, Wang L, Gong Y, et al. Study on the effects of different anti-vegf drugs on fibrovascular membranes of proliferative diabetic retinopathy[J/OL]. Photodiagnosis Photodyn Ther, 2023, 42: 103530[2023-04-14]. https://pubmed.ncbi.nlm.nih.gov/37060987/. DOI: 10.1016/j.pdpdt.2023.103530.
47.
48.
49.
50.
51.
52. Li S, Tao Y, Yang M, et al. Aflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema: a 12-month clinical trial[J/OL]. Front Endocrinol (Lausanne), 2024, 15: 1286736[2024-02-22]. https://pubmed.ncbi.nlm.nih.gov/38455651/. DOI: 10.3389/fendo.2024.1286736.
53.
54. Gao J, Tao L, Jiang Z. Alleviate oxidative stress in diabetic retinopathy: antioxidant therapeutic strategies[J/OL]. Redox Rep, 2023, 28(1): 2272386[2023-12-02]. https://pubmed.ncbi.nlm.nih.gov/38041593/. DOI: 10.1080/13510002.2023.2272386.
55.
56.
57.
58. Lee CH, Lui DT, Cheung CY, et al. Circulating AFABP, FGF21, and PEDF levels as prognostic biomarkers of sight-threatening diabetic retinopathy[J/OL]. J Clin Endocrinol Metab, 2023, 108(9): e799-e806[2023-08-18]. https://pubmed.ncbi.nlm.nih.gov/36856742/. DOI: 10.1210/clinem/dgad112.
59.

Previous Article
Research progress in the treatment of diabetic retinopathy
Next Article
Research progress on the mechanism and treatment of endoplasmic reticulum stress in diabetic retinopathy

Chinese Journal of Ocular Fundus Diseases

Research progress on the effects of different dosing regimens of anti-vascular endothelial growth factor drugs on diabetic retinopathy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content